First primate studies to show cognitive benefits of the protein klotho could be a step towards clinical applications.
Researchers at NCMM have demonstrated the mechanisms behind the activation of Aurora B, a central conductor of cell division. Their findings, now published in eLife, can lay the foundations for developing new cancer drugs.
Cell division is a fundamental process for all living things, where one cell divides into two cells. It allows for a human being to grow from a single fertilized egg cell, for wounds to heal, and for dead cells within your body to be replenished with new cells.
By the time you have read this sentence, millions of cells throughout your body have divided.
A new index that takes neighborhood and community conditions into consideration could be a useful measure for identifying preterm birth risk, a study published in JAMA Network Open found.
“We’re looking at outcomes at the county level or exposures at the county level,” Sara C. Handley, MD, MSCE, an attending neonatologist at The Children’s Hospital of Philadelphia and instructor of pediatrics at the University of Pennsylvania Perelman School of Medicine, told Healio.
“So, what was the maternal vulnerability in each U.S. county, and then what were the rates of preterm birth in those counties? We looked at different types of vulnerabilities that were developed through the Maternal Vulnerability Index, and also the type of severity of preterm birth,” Handley explained.
Coming from a long line of educators all the way back to her great-grandmother, Toysha Mayer, D.H.Sc., swore she’d choose a different career.
“I didn’t want to teach, but after becoming a histotechnologist, I ended up working in teaching hospitals. It was a natural progression for me to work with new technicians, residents and fellows,” says the assistant professor and associate program director for Histotechnology at The University of Texas MD Anderson Cancer Center School of Health Professions (SHP). Histotechnologists prepare patients’ tissues so our pathologists can make precise diagnoses for diseases like cancer.
In this online immunology course, you’ll learn about processes that enable our immune systems to respond to threats, and understand emerging treatments.
Finding new drugs – called “drug discovery” – is an expensive and time-consuming task. But a type of artificial intelligence called machine learning can massively accelerate the process and do the job for a fraction of the price.
My colleagues and I recently used this technology to find three promising candidates for senolytic drugs – drugs that slow ageing and prevent age-related diseases.
Senolytics work by killing senescent cells. These are cells that are “alive” (metabolically active), but which can no longer replicate, hence their nickname: zombie cells.
DISCLOSURE: Longevity. Technology (a brand of First Longevity Limited) has been contracted by the company featured in this article to support its current funding round. Qualifying investors can find out more via the Longevity. Technology investor portal.
British regenerative medicine company Videregen is on a mission to cure chronic diseases and is targeting the human immune system through its work to regenerate the thymus. Building on groundbreaking work conducted at the Francis Crick Institute, Videregen believes its technology holds the potential to restore the function of the aging immune system. The company is already approved for initial clinical trials of its technology in respiratory disease and is working towards trials of its regenerative thymus technology within three years.
Longevity Technology: The thymus is a small but important organ in the immune system and is responsible for the development and maturation of critical T cells. It plays a key role in our early development, but declines significantly as we age, along with the functionality of our immune system, and its decline is linked to several age-related and chronic diseases. Videregen is betting that its technology can help restore the thymus, potentially rejuvenating our immune system in the process. To learn more, we spoke to the company’s CEO, Dr Steve Bloor.
A stem cell therapy treatment developed by Duke-NUS Medical School researchers for heart failure has shown promising results in preclinical trials. These cells, when transplanted into an injured heart, are able to repair damaged tissue and improve heart function, according to a study published in the journal npj Regenerative Medicine.
Longevity. Technology: The most common cause of death worldwide is ischemic heart disease, which is caused by diminished blood flow to the heart. When blood flow to the heart is blocked, the heart muscle cells die – a condition termed myocardial infarction or heart attack, something that happens to 805,000 people a year in the US [1].
In the Duke-NUS study, a unique new protocol was used where pluripotent stem cells were cultivated in the laboratory in order to grow into heart muscle precursor cells – these cardiomyocyte progenitors can develop into various types of heart cells, through a process called cell differentiation in which dividing cells gain specialised functions. During preclinical trials, the precursor cells were injected into the area of the heart damaged by myocardial infarction, where they were able to grow into new heart muscle cells, restoring damaged tissue and improving heart function.
Tanya Lewis: Hi, and welcome to Your Health, Quickly, a Scientific American podcast series!
May people worry that infectious pathogens will become resistant to current first-line therapies like antibiotics. Bacteria and other infectious diseases evolve and change to meet the needs of their environment and overcome treatments like these. Cancer is a well-known case in which the tumor cells evolve and become resistant to immunotherapy and other targeted treatments. Cancer is a prime example, because it rapidly divides and the mechanism by which it progresses allows tumor cells to avoid or overcome therapies. However, bacterial diseases are also common infections that can rapidly evolve. The World Health Organization (WHO) has even warned against a time in which antibiotics will not work. If this were the case, minor illnesses such as the common cold, could become fatal. The worry of antibiotic resistance is partly the reason we get yearly vaccinations. The Center for Disease Control (CDC) best predicts which viral infections will persist in the following year. A multitude of data is included in this prediction including the following:
